AI Is Extending the Economic Life of the World’s Factories

Artificial intelligence is beginning to change how manufacturers think about one of their largest capital commitments: the machinery already installed inside their factories. Rather than replacing ageing production equipment with entirely new automated plants, manufacturers are increasingly using sensors, machine data and AI-assisted monitoring to understand when equipment is deteriorating and intervene before a failure interrupts production. The potential financial impact can be substantial. Unplanned equipment failure can stop an entire production line, disrupt deliveries, increase labour costs and create problems elsewhere in the supply chain.

At AI4 2026 in Las Vegas, manufacturing executives from Kimberly-Clark, BlueScope and commercial food-equipment producer Henny Penny discussed how predictive maintenance is moving from isolated technology experiments towards a broader strategy for managing industrial assets. The discussion, moderated by Woven Capital, Toyota’s growth-stage investment arm, highlighted an important shift in industrial AI. Predictive maintenance itself is not new. Manufacturers have monitored vibration, temperature, electrical current and other machine characteristics for decades. What has changed is the ability to collect information more cheaply, combine it with historical maintenance records and use machine-learning systems to identify patterns that employees may not recognise until equipment is much closer to failure.

Traditional industrial maintenance generally follows three approaches. Equipment can be repaired after it fails, serviced according to a predetermined schedule whether it requires intervention or not, or monitored continuously so maintenance can be performed when the data indicates that deterioration is developing. The third approach has become considerably more practical as sensors have become cheaper and AI has improved the ability to interpret large quantities of operational information. For manufacturers, the objective is not necessarily to eliminate equipment failure. It is to convert unexpected downtime into planned downtime. Knowing several weeks in advance that a bearing, motor, pump or other critical component is deteriorating gives plant managers the opportunity to schedule repairs, secure spare parts and reorganise production rather than dealing with an emergency shutdown.

Kimberly-Clark described how vibration and electrical-current monitoring is already being used across parts of its industrial asset base. Equipment including bearings, valves and rotating machinery generates signatures that can indicate changes in operating condition. In chemical processes, similar monitoring can identify problems such as leaking valves or changes that could affect the production process. One particularly expensive problem is an unexpected break during continuous manufacturing. According to the company’s presentation, an emergency interruption on some production lines can carry costs reaching approximately $250,000 per hour. Predictive monitoring can potentially identify deteriorating conditions weeks beforehand, allowing the company to move maintenance into a controlled production window.

That distinction is economically important. A machine may still require exactly the same repair, but the financial consequences can be dramatically different depending on when the work takes place. Planned maintenance allows managers to adjust production schedules, prepare replacement components and coordinate employees before the line is stopped. An unexpected breakdown can simultaneously create lost production, overtime, emergency repair costs and missed customer commitments.

The panel also challenged the assumption that manufacturers need to replace old equipment before they can benefit from AI. Industrial facilities frequently contain machinery that has operated successfully for decades. In capital-intensive sectors such as steel, replacing functioning equipment simply because it lacks modern digital controls can be difficult to justify. BlueScope described machinery that may have been installed 20 or 30 years ago but remains capable of safely producing the required product. Historically, connecting such assets to modern monitoring infrastructure could require substantial investment in controllers, wiring and plant systems. In some cases, the cost of digitally upgrading an individual motor or component could reach well into six figures, effectively preventing the investment.

Wireless monitoring and lower-cost sensing technologies are changing those economics. Instead of rebuilding the underlying machine, manufacturers can increasingly add external monitoring equipment and connect operational information to newer analytical platforms. That can allow a decades-old asset to participate in a modern predictive-maintenance programme without requiring a complete equipment replacement. For industrial property owners and manufacturing companies, this creates an important capital-allocation question. Older machinery is not necessarily obsolete simply because it predates connected manufacturing. If equipment remains safe, reliable and capable of producing the required quality, digital monitoring may extend its useful economic life considerably.

The same logic can apply to entire industrial facilities. The future of manufacturing may therefore involve fewer completely automated greenfield factories than some technology forecasts suggest. A substantial portion of industrial AI investment could instead flow into retrofitting and digitally enhancing existing plants. However, the panel repeatedly warned against adding sensors simply because the technology is available. Collecting additional information creates cost, complexity and cybersecurity exposure. Every connected industrial device represents another potential access point into operational technology infrastructure, while the resulting data still needs to be stored, analysed and converted into action.

A factory does not necessarily benefit from receiving dozens of different signals from a machine when one reliable indicator would provide enough information to make the maintenance decision. The value comes from identifying which measurement matters and what employees should do when it changes. Kimberly-Clark illustrated the issue through its large manufacturing operation at Beech Island, South Carolina, where parts of the industrial infrastructure are many decades old. Some equipment continues to contain analogue components because converting every element to digital technology would create substantial cost and potentially require production downtime that cannot be economically justified.

This is where the economics of industrial AI become more complicated than simply comparing the price of sensors with the cost of a machine. Manufacturers need to consider the total cost of ownership created by additional connected equipment, software licences, cybersecurity, data infrastructure and long-term maintenance. The panel provided an example of a predictive-maintenance project that successfully detected a pump problem but still failed economically. The technology could identify the condition, but doing so required sufficiently sophisticated equipment that the monitoring system cost too much relative to the value of the pump and the consequences of its failure. The technically successful project was therefore discontinued.

That example captures one of the most important lessons from the discussion. Not every failure needs to be predicted. Sometimes the most rational maintenance strategy is to keep a replacement component nearby and allow the existing one to run until it fails. The decision depends on criticality. A relatively inexpensive component with redundancy and little effect on production may not justify continuous monitoring. A single component capable of shutting down an entire production process can justify considerably greater investment.

Henny Penny illustrated this through commercial restaurant equipment. A restaurant fryer can contain multiple heating elements, meaning failure of one may still allow the kitchen to continue operating. A critical pump, however, may have no equivalent redundancy. If that component fails, the restaurant can lose its ability to produce an important part of its menu. Predictive maintenance therefore needs to begin with the economic consequence of failure rather than with the technology capable of detecting it. Manufacturers need to understand what happens when the asset stops, how quickly it can be repaired, whether another machine can take over and how much the disruption costs.

The required warning period also varies significantly. Technology companies frequently market predictive systems around their ability to identify failures weeks in advance, but such long forecasts may provide little additional value. Henny Penny found that equipment problems in restaurants can already take several days to progress from initial failure to technician arrival because employees first need to report the problem and service teams then need to dispatch someone. For certain critical equipment, knowing four or five days before failure may therefore provide sufficient time to intervene. This illustrates why predictive maintenance cannot be standardised purely around technical performance. A model predicting a failure 30 days ahead is not automatically more valuable than one providing five days of warning. The relevant measure is whether the prediction gives the organisation enough time to take the economically appropriate action.

The return on investment can also appear in areas beyond conventional calculations of production uptime. Henny Penny reported feedback from a major restaurant customer that equipment failures increase employee stress because workers must suddenly adapt service around unavailable machinery. Avoiding unexpected breakdowns can therefore improve working conditions as well as operational performance. For large manufacturers, the consequences can extend through inventory and retail distribution. Kimberly-Clark explained that production interruptions can affect commitments to major retailers and alter the timing of product flows through warehouses and stores. A failure at the factory can consequently create costs well beyond the machine where the problem originated.

Environmental performance provides another potentially significant benefit. In chemical-intensive manufacturing, deteriorating equipment can increase the consumption or leakage of process materials before the problem becomes severe enough to stop production. Monitoring those changes can identify inefficiency earlier and potentially reduce waste, energy consumption and environmental exposure. Predictive maintenance therefore intersects increasingly with corporate sustainability strategies. Equipment that operates outside its optimal range can consume more electricity, water or raw materials. A deteriorating bearing, for example, can require more energy before the change becomes obvious to an operator. Detecting that deterioration earlier can produce both maintenance and energy savings.

However, the business case needs to capture these benefits explicitly. BlueScope argued that condition-monitoring programmes should be able to demonstrate financial payback. Manufacturers need systems for tracking not only the cost of deploying technology but the value of failures prevented, production preserved and other operational improvements. Demonstrating successful returns also helps organisations expand programmes. Once employees and management can see that a particular monitoring application has paid for itself, gaining support for deployment on additional assets becomes easier.

Scaling remains one of the industry’s largest difficulties. A predictive-maintenance model that works in one factory cannot necessarily be copied directly into another. Kimberly-Clark operates a large global manufacturing network in which plants contain equipment from different generations and vendors, integrated through different systems and maintained by employees with different operating histories. The panel summarised the problem by noting that manufacturing patterns may repeat while the underlying implementation rarely does. Similar machines can experience comparable failure modes, but the code, integrations and operational environment are seldom identical.

This complicates the economics of scaling industrial AI. A company may successfully demonstrate a predictive model on one production line only to discover that deploying it across dozens of plants requires substantial additional integration and calibration. Industrial AI therefore differs from many corporate software applications where one system can be rolled out relatively uniformly across an organisation. Individual machines can also develop their own operating signatures. Henny Penny described establishing baseline characteristics when equipment leaves the production line. Once that machine is operating at a customer location, its subsequent behaviour can be compared with its own original condition as well as with broader fleet data.

At sufficient scale, this creates potentially valuable information. A manufacturer with tens of thousands of connected machines in customer locations can identify patterns across the installed base while still recognising differences between individual units. But the risks of model errors also increase dramatically. A false maintenance alert affecting one machine is inconvenient; the same error replicated across tens of thousands of connected units can create widespread operational disruption.

Human operators therefore remain central to predictive maintenance. Experienced maintenance employees often know individual machines intimately and can recognise changes through sound, vibration or behaviour. AI needs to earn their trust rather than simply override their judgement. False alarms are particularly damaging. If a monitoring system repeatedly warns about failures that never occur, operators can quickly stop paying attention. Once that happens, even a correct warning may be ignored.

Successful implementation therefore requires collaboration between data specialists, reliability engineers, maintenance teams and machine operators. AI can identify abnormal patterns and recommend action, but employees need to understand what the warning means and what should happen next. Visualisation and notification are also critical. A sophisticated predictive model creates little value if its warning is buried inside a dashboard that nobody checks. Information needs to reach the right employee at the moment when action is still possible.

This reinforces the idea that predictive maintenance is ultimately an operational system rather than simply an AI model. Sensors, data infrastructure, analytics, notifications, maintenance processes, spare-parts availability and human decision-making all need to work together. The same complexity affects decisions over whether manufacturers should build AI capabilities internally, purchase commercial platforms or work with external partners.

The panel suggested that commodity capabilities are often better purchased. Common equipment signatures, such as bearing vibration, are not necessarily sources of competitive advantage and may already be addressed effectively by specialised vendors. Manufacturing processes that are unique to a company’s products or intellectual property can justify custom development. Kimberly-Clark pointed to manufacturing characteristics involving absorbency, chemical balances and specialised production techniques as examples where internal knowledge becomes strategically important.

The emerging model is therefore likely to combine buying, building and partnering. Manufacturers can purchase standard monitoring technologies while developing proprietary models around processes that differentiate their products. AI itself is also making internal development easier. BlueScope noted that modern AI tools allow operational and engineering teams to perform analytical and development work that previously required external consultants. This could reduce the cost of creating specialised applications and make smaller industrial AI projects economically viable.

The more important opportunity may ultimately come from combining information that already exists across the factory. Sensor readings represent only one part of the picture. Maintenance-management systems contain years of work orders, repair histories and technician comments that have historically been difficult to analyse at scale. Bringing those records together with real-time machine data can give managers a much richer understanding of asset condition. This suggests that some of the most valuable industrial AI applications may not require additional sensors at all. Existing error codes, maintenance records, production data and service histories can already contain enough information to identify useful patterns.

Manufacturers also need to consider ownership of this information when selecting technology vendors. Industrial operating data can reveal production volumes, equipment performance, proprietary processes and weaknesses within a manufacturing system. Moving that information entirely into a vendor-controlled platform can create long-term dependence. The panel warned that companies need to understand where their production data resides, who controls it and how easily it can be moved. A manufacturer that places its operational history inside a proprietary external platform can eventually find itself effectively paying ongoing rent to access information generated by its own equipment.

The issue is becoming more significant as technology vendors add AI capabilities and increase software costs. Manufacturers therefore need to consider the long-term total cost of ownership rather than simply the initial subscription price. For industrial companies and investors, the larger implication is that AI may change the economics of existing manufacturing assets before it transforms factories into fully autonomous facilities. The ability to monitor older machinery cheaply, extract information from maintenance histories and schedule interventions before failure can extend asset life and improve the productivity of capital already invested.

That could influence future industrial CAPEX strategies. Companies may find that retrofitting selected high-value assets produces better returns than replacing entire production lines. Older factories with strong physical infrastructure could remain economically competitive for longer if digital monitoring compensates for some of their technological limitations. The investment case for industrial modernisation therefore becomes more selective. Rather than spending capital uniformly across a plant, manufacturers can identify the machines whose failure carries the greatest economic consequences and concentrate technology investment there.

Predictive maintenance is consequently becoming as much a capital-allocation discipline as a technology programme. The most sophisticated model does not automatically produce the best result, and the most connected factory is not necessarily the most efficient. The real advantage comes from understanding which assets matter, which failures need to be predicted, how much warning is actually required and what action employees should take when the warning arrives.

AI is making those decisions easier by allowing manufacturers to extract more value from data that machines have been producing for years. But the factories likely to benefit most will not necessarily be those installing the greatest number of sensors or deploying the most AI. They will be the ones that use the technology selectively to keep critical equipment running, reduce unplanned downtime and extract more productive life from billions of dollars already invested in industrial assets.

Source: CIJ.World Research & Analysis Team

Dutch Healthcare Property Is Growing Faster Than Its Investment Market

Healthcare real estate is becoming one of the most closely watched parts of the Dutch property market. An ageing population is creating a long-term requirement for senior housing and care facilities, government funding is being directed towards increasing supply, and investors are searching for property capable of delivering dependable income over extended periods. The first half of 2026 appears at first glance to confirm that healthcare has already become a major investment sector. Around €847 million of activity was recorded by one leading market measure. Look beneath that figure, however, and the market is considerably more complicated.

Another assessment of Dutch healthcare transactions records approximately €550 million across 27 deals during the same six months. The difference largely reflects the treatment of the Dutch healthcare portfolio involved in the combination of Aedifica and Cofinimmo. Including the portfolio produces a much larger investment total. Excluding the corporate combination from conventional property turnover provides a figure closer to the amount of healthcare real estate bought and sold through ordinary investment transactions. Neither approach makes the underlying healthcare story disappear. The approximately €550 million of conventional activity was still substantially higher than the roughly €272 million recorded during the first half of 2025. The market therefore expanded strongly even without relying on the exceptional corporate event. The difference between the two 2026 totals instead reveals something important about the maturity of the sector: Dutch healthcare property remains small enough for a single large transaction to transform the headline numbers.

The €210.5 million Nightingale portfolio transaction demonstrates both the opportunity and the concentration. A deal of that size provides clear evidence that substantial capital can be deployed into Dutch healthcare property when an appropriate portfolio becomes available. At the same time, one transaction accounted for a significant proportion of conventional first-half investment. That is very different from a deep market in which numerous large assets and portfolios trade regularly. The long-term case for expanding the sector is nevertheless powerful. The Netherlands estimates that approximately 290,000 additional homes suitable for older residents will be needed by the end of 2030. Plans exist for a substantial proportion of that requirement, but tens of thousands of additional projects are still needed, particularly in forms of housing that combine independent living with communal facilities or the ability to provide increasing levels of care.

That requirement creates an investment market much broader than traditional nursing homes. Senior apartments, clustered housing, assisted living, nursing facilities, clinics, medical centres and rehabilitation properties can all form part of the healthcare real estate universe. They may respond to the same demographic trend, but they do not represent the same investment. Senior housing can behave much like residential property. Demand depends on location, affordability, accessibility and the number of older households seeking suitable accommodation. Residents can live largely independently while obtaining healthcare separately when required. At the other end of the spectrum, a specialised nursing facility may depend almost entirely on a professional care provider capable of operating the building and supporting residents with complex needs.

For investors, this distinction makes the organisation occupying or operating the property unusually important. A long lease can provide visibility over future rental income, but the value of that lease ultimately depends on whether the tenant can afford its obligations. Healthcare operators have to manage wages, energy, regulation and increasingly complex care requirements while remaining within the financial structure of the Dutch healthcare system. Rent therefore cannot be analysed separately from the economics of care. Contractual indexation may protect investors against inflation, but continued increases in property costs become difficult if an operator’s revenues do not rise sufficiently to absorb them. A lease that looks attractive on paper can become less secure if the business responsible for paying the rent is under sustained financial pressure.

The labour market adds another layer of risk. The Netherlands expects significant shortages of healthcare workers during the coming decade, with elderly care particularly exposed. This creates a paradox for healthcare property. The ageing population increases demand for facilities while simultaneously increasing the number of employees required to operate them. A modern nursing home in an area with rapidly increasing numbers of elderly residents may therefore appear to have exceptionally strong demand. But if its operator cannot recruit enough nurses and carers, demographic demand alone cannot guarantee successful operation. For investors, access to labour could become increasingly relevant when assessing locations. That means looking beyond the traditional healthcare catchment area. Public transport, commuting times and the availability and cost of housing for employees can influence whether a facility is practical to operate. A location that works for residents but not for staff may ultimately create difficulties for the tenant and therefore for the property owner.

Development presents another challenge. The Netherlands does not simply need more ordinary apartments occupied by older people. A substantial part of the requirement involves homes designed so residents can continue living independently as their mobility declines or their need for care increases. Such properties can require step-free layouts, wider doors and corridors, larger bathrooms, lifts and additional space allowing healthcare workers to assist residents. Communal facilities may also be required to reduce isolation and support services within the development. These features can increase construction costs while using space that would otherwise generate rent. Government support reflects the difficulty of delivering these properties. Funding made available during 2026 is intended to encourage the development of care-ready homes and shared facilities, while additional money has been committed for the coming years to accelerate senior housing. Public intervention is therefore helping to create a development pipeline, but private capital will still need projects where land costs, construction expenditure and achievable income produce acceptable returns.

The opportunity is not limited to new construction. Existing offices, hotels and other buildings could potentially be adapted for senior housing or healthcare uses. In a country simultaneously dealing with housing shortages and obsolete commercial property, conversion can appear attractive. The physical reality is more complicated. Buildings designed for offices or hotels do not automatically work for people with reduced mobility or for healthcare operators. Floor layouts, lifts, fire safety, daylight, bathrooms, circulation space and access for staff can determine whether conversion is financially realistic. Some buildings will adapt successfully. Others may require so much reconstruction that demolition and redevelopment become more economical. Healthcare property therefore cannot simply become an automatic destination for unwanted commercial property. The building must work for the people receiving care and for those providing it.

Location requirements also differ across the sector. Independent senior housing benefits from proximity to shops, public transport, doctors and social facilities. Nursing homes require sufficient staff within reach. Medical centres need accessible locations serving substantial populations. Rehabilitation facilities may require specialised accommodation and different transport arrangements. These differences make healthcare property more operationally complex than its reputation for long leases and defensive demographic demand sometimes suggests. They also explain why transparency matters. The Dutch healthcare transaction market does not yet provide the same depth of information available in some established property sectors. Limited disclosure of rental details across transactions makes it harder to compare assets and determine precisely how investors are pricing tenant strength, lease conditions and building quality.

Headline yields alone cannot solve that problem. A property producing a higher return may have a weaker operator, greater future capital requirements or limited possibilities for alternative use. Another asset producing a lower return may occupy a superior location, have a stronger tenant and remain adaptable if healthcare delivery changes. Investors therefore need to understand both the real estate and the care business behind it. This could encourage further specialisation within the investment market. Residential investors can target senior apartments and independent living. Dedicated healthcare funds can concentrate on nursing and assisted-living properties. Institutional investors seeking long-duration income can acquire modern facilities occupied by financially strong organisations. Investors prepared to take development risk can pursue conversions and new projects. Over time, this could turn Dutch healthcare property into several related institutional markets rather than one asset class.

One of the most interesting models may be developments capable of supporting residents through different stages of later life. Independent apartments, communal facilities and access to care can be combined so that residents do not necessarily need to leave their neighbourhood when their circumstances change. As their needs increase, additional services can be provided around them. This has implications for the wider housing market. Building attractive homes for older residents can encourage households to move from properties that no longer suit their needs. Larger existing homes can then become available to younger households and families. Senior housing can therefore contribute to housing-market movement rather than simply adding another specialist category of accommodation. For investors, this strengthens the connection between healthcare and residential property. Some of the largest opportunities created by ageing may ultimately involve housing where care can be introduced when required rather than traditional institutional facilities.

The first-half 2026 investment figures should be understood within this much larger structural change. The €847 million headline demonstrates the scale the market can appear to reach when a major corporate portfolio event is included. The approximately €550 million spread across 27 conventional transactions gives a clearer indication of the underlying investment market. That underlying figure is arguably the more significant one. It more than doubled from the comparable period of 2025, demonstrating that investor activity strengthened even without the exceptional transaction. But it also shows how far the sector still has to develop. A mature institutional property market requires regular supply, multiple large buyers and sellers, transparent rental evidence and sufficient transaction volume that individual deals do not radically alter annual statistics. Dutch healthcare property is progressing towards that position, but it has not necessarily reached it yet.

Demographics provide a strong foundation. The Netherlands will need substantially more senior housing and care-related property. Government funding is supporting development, while institutional and specialist investors are demonstrating an appetite for the sector. The difficult part is turning that demand into investible buildings. Healthcare operators must remain financially sustainable. Facilities need enough employees. Development costs must be supported by achievable rents. Buildings need to remain suitable as care requirements change. Investors need reliable information about leases and transactions, while enough assets must reach the market to allow capital to build diversified portfolios.

Those challenges do not weaken the healthcare property story. They define it. The Netherlands is developing a larger healthcare real estate market because the demographic requirement is becoming impossible to ignore. The approximately €550 million invested through 27 transactions during the first half of 2026 suggests that this development is already translating into genuine investment activity. The larger headline number makes the sector look bigger. The underlying transactions make the investment story more convincing.

Source: CIJ.World Research & Analysis Team

AI Is Accelerating Drug Discovery, but Clinical Development Is Becoming the New Bottleneck

Artificial intelligence is dramatically increasing the speed at which pharmaceutical companies can identify potential drug candidates, analyse biological information and automate research tasks. But as the earliest stages of drug development become faster, another problem is becoming increasingly visible: the rest of the pharmaceutical development system cannot necessarily move at the same speed. That emerging imbalance was one of the central themes of a life-sciences panel at AI4 2026 in Las Vegas, where representatives from pharmaceutical companies, clinical research, biotechnology and AI infrastructure discussed how artificial intelligence is changing the journey from laboratory research to medicines reaching patients.

The panel was moderated by Bryson Tombidge, CEO of Tono Health, and included Talia Fakhoury, Chief AI and Regulatory Strategy Officer at Parexel and a former US Food and Drug Administration official; Laura Boykin-Okalebo, a computational biologist working with AI infrastructure provider Nebius; Patrick Lerch, Senior Vice President of Clinical Data Sciences at Gilead Sciences; and an AbbVie executive responsible for clinical systems, digital operations and AI implementation in clinical development. The discussion suggested that AI’s biggest contribution may ultimately come not simply from discovering more molecules, but from reducing the time and resources required to move promising treatments through clinical development.

The starting point was a striking change taking place in pharmaceutical research. AI can increasingly analyse biological targets, screen potential compounds, model proteins and optimise candidate molecules considerably faster than traditional laboratory processes alone. Research teams can therefore produce larger numbers of potential drug candidates in shorter periods. That represents an important scientific advance, but it also risks transferring pressure further along the pharmaceutical development chain. A molecule that appears promising still needs to progress through preclinical testing and several stages of human clinical trials before regulators can consider approving it. Those processes remain expensive and time-consuming, and some elements cannot simply be accelerated through additional computing power. Human biology operates according to its own timetable, while regulators continue to require evidence demonstrating that medicines are safe and effective.

Lerch described the resulting flow of potential compounds emerging from research as a growing wave heading towards clinical development. For pharmaceutical companies, this creates a resource allocation problem. AI may generate more scientifically plausible opportunities, but companies still have finite budgets, clinical-development teams, trial sites and eligible patients. Every decision to advance another molecule therefore remains an investment decision. This means the industry’s next challenge is increasingly about improving the efficiency of clinical development itself.

AbbVie is examining the critical path between the start of clinical development and the eventual submission of a medicine for regulatory approval, looking for individual stages where AI can remove delays. Potential applications include preparing clinical systems faster, accelerating analysis after trials are completed and assisting with preparation of clinical study reports and regulatory documentation. The objective is not necessarily to eliminate large numbers of jobs or simply reduce operating expenses. The more strategically important measurement is time. Removing several weeks from multiple stages of development can eventually shorten a programme by months. Across a large pharmaceutical portfolio, those savings can become commercially significant while potentially allowing successful treatments to reach patients earlier.

Gilead is approaching the opportunity through both scientific and operational applications. On the scientific side, AI is being explored in medical imaging to analyse tumour burden and help researchers evaluate how cancer treatments are performing. Faster analysis could allow development teams to make earlier decisions about whether a programme should progress to another clinical phase. On the operational side, one of the more immediate opportunities involves software development and statistical programming. Pharmaceutical companies produce substantial quantities of specialised code to prepare, transform and analyse clinical data. Much of this work is created for individual studies or analyses. AI-assisted coding can accelerate these processes while retaining validation and human oversight, allowing information to move through the clinical-development system more quickly.

The distinction between speed and useful progress emerged repeatedly during the discussion. AI can produce an answer or complete a task considerably faster, but speed alone does not guarantee that the organisation is moving in the correct direction. Pharmaceutical companies operate in a highly regulated environment where inaccurate analysis can ultimately affect regulatory submissions and patient safety. Human oversight therefore remains particularly important. AI-generated work that feeds into regulatory documentation cannot simply be accepted because it was produced quickly. Companies need quality controls capable of checking outputs while ensuring that automation does not introduce errors or unsupported conclusions into clinical-development processes.

This is creating a different challenge from the one facing many other industries adopting generative AI. Pharmaceutical companies need to balance automation against scientific evidence, regulatory requirements and patient risk. An AI system capable of reducing a four-week analytical task to a day may create enormous value, but only if the resulting work meets the same or higher quality standards. Clinical research organisations are already reporting measurable improvements in some administrative processes. Fakhoury said Parexel has been using AI to reduce the time required to prepare regulatory documentation and regulatory-grade datasets. The broader significance is that these relatively routine processes sit between important milestones in drug development. Accelerating enough of them could collectively reduce the time between clinical phases.

The more ambitious opportunity involves changing the structure of clinical trials themselves. One area receiving increasing attention is the use of computational models to estimate how patients might have responded without receiving an experimental treatment. In carefully designed circumstances, these approaches could supplement information from traditional control groups and potentially reduce the number of patients required to receive a placebo. This could be particularly valuable for rare diseases, where finding sufficient numbers of eligible patients is difficult and allocating some participants to placebo groups can make recruitment even harder. AI combined with historical clinical information and statistical modelling may eventually allow researchers to extract more information from smaller patient populations.

However, the term “digital twin” is increasingly being used to describe several different technologies. The panel cautioned against treating it as a single concept. In some applications, it refers to statistical models used to estimate a patient’s likely response in a control group. Elsewhere, it can refer to synthetic or external control groups built from historical health records, while other organisations use the term for virtual representations of biological systems or operational processes. The underlying opportunity is nevertheless significant. Better modelling could help pharmaceutical companies estimate treatment effects more accurately, determine appropriate trial sizes and potentially reduce uncertainty before expensive late-stage studies begin.

AI can also address another persistent clinical-trial problem: finding patients. Matching patients to studies currently requires analysing complex eligibility criteria against fragmented healthcare information. AI can potentially search electronic health records more efficiently and identify patients whose medical profiles make them suitable for particular trials. Yet this immediately exposes one of the industry’s largest structural problems. Healthcare information remains fragmented across hospitals, insurers, laboratories, research organisations and different technology systems. In the United States in particular, data required for sophisticated patient matching may exist across numerous organisations that cannot easily exchange it. AI therefore does not eliminate the pharmaceutical industry’s data problem. In many cases it makes the importance of that problem more visible.

The same applies to the transition between animal research and human clinical trials. Despite advances in laboratory science, predicting how findings from animal models will translate into humans remains difficult. AI could potentially improve estimates of appropriate first-in-human doses, likely treatment effects, safety risks and other biological responses, but this remains one of the hardest problems in drug development. The panel identified this translational stage as potentially more important than simply designing molecules faster. If AI can substantially improve predictions about which treatments are most likely to work safely in humans, pharmaceutical companies could avoid committing years of development and substantial capital to programmes that eventually fail.

Until that improves, clinical development is likely to remain slower than AI-driven discovery. Researchers may become capable of generating candidate molecules at unprecedented speed, but each candidate still enters a system requiring scientific validation, clinical trials, regulatory scrutiny and real patients. This creates the possibility of a pharmaceutical pipeline bottleneck. Rather than suffering from too few promising compounds, companies could increasingly face more candidates than their clinical-development organisations can realistically process.

Compute infrastructure represents another emerging constraint. Modern biological AI models can require substantial GPU capacity, particularly when researchers are working with genomics, medical imaging, molecular simulations and increasingly sophisticated foundation models. Boykin-Okalebo said demand for advanced computing infrastructure continues to exceed available supply in parts of the market. For biotechnology start-ups without the financial resources or technology infrastructure of global pharmaceutical companies, access to suitable computing capacity can determine whether research progresses at all.

Research computing is consequently becoming part of biotechnology business planning. A start-up may have promising science and financing but still struggle if it cannot secure the computing resources required to train or operate its models. This means founders and investors increasingly need to consider compute requirements alongside laboratory space, clinical strategy, intellectual property and capital requirements. The infrastructure challenge is not simply obtaining GPUs. Healthcare and pharmaceutical workloads frequently involve sensitive patient information, creating additional requirements around storage, encryption, cybersecurity and data location. Computing capacity and data storage therefore need to be designed together.

If sensitive information must remain in a particular jurisdiction while the available computing infrastructure is located elsewhere, the theoretical performance of the AI hardware becomes less relevant. The architecture needs to satisfy privacy and regulatory requirements while allowing data to move efficiently between storage and compute. This creates an important infrastructure investment angle around the expansion of AI in life sciences. Data centres supporting pharmaceutical and healthcare workloads may need configurations specifically designed for regulated information, high-performance computing and secure connections to large datasets. As biological AI becomes more sophisticated, proximity between compute and data could become increasingly important.

Regulation itself may not be as significant an obstacle as some companies assume. Drawing on her previous experience at the FDA, Fakhoury argued that many operational uses of AI within pharmaceutical companies sit outside direct regulatory oversight. AI used to help prepare documents or improve internal processes is different from a system whose output becomes evidence supporting the safety or effectiveness of a medicine. She cautioned companies against automatically applying validation procedures created for older deterministic software systems to every modern AI application. Excessively conservative interpretations can increase costs and delay projects without necessarily improving patient protection.

The more appropriate approach is to evaluate systems according to their actual risk and intended use. AI directly influencing clinical evidence or patient safety requires far greater scrutiny than technology automating an internal administrative task. The European environment adds another layer through data-protection requirements such as GDPR, particularly when patient information is involved. As clinical research becomes increasingly international, pharmaceutical companies and their technology providers need infrastructure capable of operating across different regulatory and data-governance regimes.

This reinforces the importance of global clinical research. AI may accelerate the creation of new drug candidates, but trials still require patients. Access to diverse patient populations, healthcare systems and clinical sites could therefore become even more strategically important as the number of potential therapies entering development increases. The panel also highlighted the importance of including more geographically diverse researchers and datasets in AI development. Models trained predominantly on information from limited populations may perform differently when applied elsewhere. Expanding participation in AI-enabled medical research could improve both scientific representation and the ability to develop treatments for wider populations.

Another obstacle is organisational rather than technological. Pharmaceutical companies cannot simply provide employees with AI tools and expect productivity to improve automatically. Existing processes were generally designed around human workflows and older technology, meaning many need to be redesigned before AI can deliver its full benefit. Lerch argued that implementation and change management are becoming some of the biggest challenges. Employees need to understand why workflows are changing, where AI fits into their responsibilities and how their expertise remains essential. Without that engagement, even technically successful systems may struggle to achieve widespread adoption.

The same lesson applies to pharmaceutical executives. Ordering an organisation to use AI without identifying specific problems can create numerous disconnected experiments with little measurable impact. Scientists, clinicians, engineers and data specialists need to work together to identify tasks where AI can genuinely improve outcomes. Productivity may also initially decline. Employees need time to learn new systems, organisations must redesign processes and AI-generated work requires validation. The benefits may only emerge after those initial implementation costs have been absorbed.

The economics of running AI are becoming another consideration. Companies that initially focused almost entirely on model performance are increasingly paying attention to the computing resources consumed by large-scale AI applications. As usage expands across thousands of employees and complex scientific workloads, the cost of inference and token consumption can become material. This introduces another layer to the investment calculation. Pharmaceutical companies need to decide not only whether an AI application works, but whether the value it produces justifies the infrastructure and computing resources required to operate it at scale.

Despite these challenges, the panel suggested that the industry’s direction has changed fundamentally. AI is already producing measurable value in specific areas of pharmaceutical research and clinical development. The next question is whether those improvements can be connected across the entire drug-development chain. If research becomes dramatically faster while clinical trials improve only incrementally, the bottleneck simply moves downstream. The pharmaceutical industry could find itself with more promising compounds than it has patients, trial sites, regulatory capacity or development resources to process.

The larger opportunity is therefore to apply AI across the complete journey from scientific discovery to clinical evidence. Molecule design, translational biology, trial design, patient recruitment, clinical monitoring, data analysis, regulatory preparation and post-market evidence all represent potential areas for improvement. The biggest gains may come when those individual applications begin operating as part of a connected development system rather than separate AI projects.

For pharmaceutical companies, that could fundamentally change the economics of innovation. Reducing development by several months can have significant commercial value. Improving the probability that a candidate entering an expensive clinical programme will ultimately succeed could be considerably more valuable. For patients, the measurement is simpler. The value of faster molecule discovery remains limited until the resulting medicine reaches the people who need it.

AI has begun accelerating the front end of pharmaceutical research. The next stage of the transformation will be determined by whether the industry’s clinical, digital and physical infrastructure can accelerate with it.

Source: CIJ.World Research & Analysis Team

Pharma’s AI Spending Is Rising, but the Real Breakthrough May Be Better Decisions

Artificial intelligence has attracted enormous investment across the pharmaceutical industry, yet the promised productivity revolution has not arrived at the same speed. Drug development remains expensive, clinical programmes remain lengthy and many AI initiatives are still struggling to move beyond demonstrations and pilot projects. That contradiction formed the central argument of a presentation by Kris Kaneta, Chief Product & Innovation Officer at Norstella, during AI4 2026. Kaneta’s message was that the pharmaceutical industry’s biggest AI problem may no longer be access to powerful models, but the inability to convert those models into trusted systems capable of supporting complex decisions involving billions of dollars, years of development and ultimately patients waiting for new treatments.

The timing of the discussion is significant. Pharmaceutical companies have spent heavily on digital technologies, data platforms and artificial intelligence, while the underlying economics of drug development remain difficult. Industry research continues to show rising development costs and long clinical timelines. AI may eventually help address those pressures, but deploying more tools does not automatically make pharmaceutical research more productive. Kaneta characterised the problem as a gap between AI demonstrations and actual decision-making. Pharmaceutical organisations have accumulated pilots, prototypes and proof-of-concept projects that can generate impressive outputs but frequently struggle when they encounter real business processes. The reasons are not necessarily failures of the underlying AI models. A system may work technically while lacking the data, context or workflow integration required to make it useful inside a pharmaceutical company.

That distinction matters because many decisions in life sciences are unusually consequential. Companies must decide which molecules deserve further investment, whether compounds should be developed for additional diseases, how clinical trials should be designed, where studies should be conducted, which investigators should participate and how medicines should ultimately reach patients. A mistake at an early stage can influence years of subsequent investment. Unlike editing a document or generating marketing material, many pharmaceutical decisions cannot simply be reversed once significant capital has been committed. This raises the standard that AI must meet before executives and scientists are willing to rely on it. A plausible answer is not enough. Users need to understand where information came from, whether the underlying evidence is current and whether the system has enough understanding of the specific pharmaceutical problem to produce something useful.

Kaneta argued that trust in these systems rests on several fundamental qualities. Outputs need to be traceable to credible information, they need to remain sufficiently reliable when similar questions are repeated, they must reflect the context of the job being performed, and they ultimately need to influence a real decision or action rather than simply produce an interesting response. That is a much higher threshold than the one required for a successful AI demonstration. A generic language model, for example, can produce a convincing summary of a therapeutic market, but pharmaceutical competitive intelligence requires more than assembling publicly available information. Analysts need to understand whether drugs remain in development, whether trials have been terminated, where regulatory approvals are pending, how competitors’ programmes are changing and how those developments affect a particular company’s strategy. An answer that includes a discontinued product or misses a recently approved medicine may still read perfectly well, yet it could lead to the wrong commercial conclusion.

This is one reason domain-specific data is becoming increasingly valuable in the AI economy. The competitive advantage may gradually shift away from simply possessing access to a large model and towards controlling well-structured, reliable and continuously updated information that gives the model meaningful context. In pharmaceutical markets, that information is spread across numerous areas. Drug pipelines, clinical trials, investigators, regulatory decisions, payer policies, reimbursement, market access, real-world patient data and commercial forecasts may all influence a single strategic decision. Historically, much of this information has existed in separate systems and organisational departments. Business development may maintain different intelligence from market access teams, while clinical development, forecasting and commercial teams use their own databases and analytical processes. Artificial intelligence creates an opportunity to connect these information environments, but only if the underlying data infrastructure is built to support that connection.

Norstella’s response has been to develop Atlas, an agent-based platform designed to combine its pharmaceutical datasets and intelligence across different parts of the drug-development lifecycle. Rather than creating one general AI assistant for every pharmaceutical task, the approach involves developing systems around particular professional roles and decisions. That distinction could become important across enterprise AI more broadly. A competitive intelligence analyst, clinical-trial specialist and market-access professional may all use artificial intelligence, but they do not need the same information or reasoning process. The system therefore needs to understand the objective of the user, not simply retrieve documents containing related words.

Kaneta used the analogy of giving an executive a thousand interns. The additional manpower could theoretically produce enormous output, but only if those workers were given precise instructions, reliable information and a clear definition of what a successful result should look like. Artificial intelligence creates a similar management challenge at vastly greater scale. An organisation can generate huge quantities of analysis, reports and recommendations, but additional output does not automatically mean additional productivity. Without reliable context, businesses risk producing more information without improving the quality or speed of the decisions that matter.

This may help explain part of the apparent productivity paradox surrounding generative AI. Companies can automate individual tasks while the total process remains slow because the underlying decision structure has not changed. A pharmaceutical company might reduce the time required to prepare an analysis from several days to several hours, for example, yet still spend weeks validating the information, moving it between departments and securing approval before acting. The real productivity opportunity therefore lies in redesigning the complete workflow rather than accelerating isolated components. This also changes how companies should evaluate AI investments. The number of employees using an AI platform or the quantity of content generated may say relatively little about its economic value. More relevant measurements include whether clinical trials can be designed more effectively, whether investment decisions are made earlier, whether unsuitable programmes are stopped sooner and whether promising medicines reach patients faster.

The financial implications can be enormous. Drug development requires billions of dollars of capital across research, clinical testing, manufacturing preparation and commercialisation. Improving one major portfolio decision could potentially create greater value than automating thousands of routine administrative tasks. Conversely, an unreliable AI recommendation used in a high-value investment decision could destroy far more value than the technology saves elsewhere. The quality of the data underneath the system therefore becomes an investment issue in its own right. Pharmaceutical companies have accumulated decades of clinical, regulatory and commercial information, but much of it remains fragmented across departments, legacy systems and external providers. Preparing that information for AI can involve substantial expenditure on integration, data governance, metadata, cybersecurity and cloud infrastructure.

The AI transformation of pharmaceutical companies may consequently produce considerable demand for technology infrastructure without immediately appearing as productivity in drug-development statistics. Companies are effectively building a new information architecture while continuing to operate extremely complex existing businesses. The benefits may only become visible once those systems begin influencing decisions across entire development programmes rather than isolated tasks. Another concern is the increasing volume of AI-generated material entering the information environment. As generative systems produce more articles, summaries and analysis, future models may encounter material that was itself generated by other models. Without strong links to original evidence, this creates the possibility of information circulating repeatedly while becoming progressively detached from authoritative sources. That risk is particularly problematic in pharmaceuticals, where outdated or inaccurate information can materially affect investment decisions.

Traceability therefore becomes more than a technical feature. It becomes part of the organisation’s risk-management structure. Executives need to be able to understand why a system reached a conclusion and verify the underlying evidence before committing capital or changing a development strategy. The same principle applies when AI moves towards more autonomous agents. An assistant that produces information remains relatively easy for a human to review, while an agent capable of triggering subsequent actions introduces an additional level of responsibility. The more autonomy these systems receive, the more important it becomes to establish precisely what information they can access, what decisions they can influence and when human approval remains necessary.

Pharmaceutical AI is therefore likely to evolve differently from consumer generative AI. Speed and ease of use remain valuable, but trust, provenance and specialist context can be considerably more important than producing an immediate answer. This favours organisations capable of combining technology with proprietary information and deep sector expertise. It may also reshape competition among pharmaceutical information providers. Companies that historically sold databases, market intelligence and research tools increasingly have the opportunity to transform those assets into the contextual layer supporting AI agents. In this model, the underlying database becomes more valuable because artificial intelligence can interrogate it continuously and connect previously separate areas of information.

The implications extend into pharmaceutical corporate strategy. As AI systems become embedded across research, development and commercial operations, businesses may need to reconsider how departments share information. Traditional organisational silos can directly reduce the effectiveness of AI. A system attempting to evaluate a drug’s commercial opportunity, for example, becomes considerably more useful if it can connect clinical evidence with competitor activity, payer behaviour, regulatory developments and real-world patient information. Breaking down those information barriers can be as difficult as developing the technology itself.

The challenge also affects corporate investment priorities. Pharmaceutical companies may be tempted to fund numerous AI experiments because the cost of creating individual prototypes has fallen dramatically. Yet the more initiatives an organisation launches, the harder it becomes to integrate, govern and evaluate them. A smaller number of applications connected to strategically important decisions may ultimately create more value than hundreds of disconnected AI pilots. The pharmaceutical industry does not have a shortage of artificial intelligence experiments. It has a shortage of AI applications trusted enough to influence decisions that genuinely matter.

Closing that gap could determine whether the industry’s technology investment eventually translates into higher research productivity. The stakes extend beyond corporate efficiency. Longer development timelines mean patients wait longer for medicines, while escalating R&D costs affect which therapies companies are willing to pursue in the first place. If artificial intelligence can help companies identify stronger drug candidates earlier, design better clinical programmes, select more appropriate patients and make faster portfolio decisions, its economic value could ultimately be measured in both capital efficiency and time.

The next phase of pharmaceutical AI may therefore be considerably less visible than the generative AI boom that preceded it. The important innovation will not necessarily be another chatbot or increasingly powerful general-purpose model. It will be the information and decision infrastructure sitting underneath those technologies. For pharmaceutical companies, the central question is shifting from how much AI they are using to whether that AI can be trusted to help make better decisions when billions of dollars and years of drug development are at stake. Until that happens consistently, the industry may continue experiencing the same paradox: increasingly sophisticated artificial intelligence operating inside a drug-development system that remains expensive, slow and difficult to change.

Source: CIJ.World Research & Analysis Team

Greek Property Investment Is Growing, but the Buyer Pool Remains Narrow

Greece’s commercial real estate market maintained its momentum during the first half of 2026, attracting approximately €1.27 billion of investment. The total was 5.8% higher than in the corresponding period of 2025, providing further evidence that the country remains capable of drawing substantial capital into property despite a more demanding financing environment and continued uncertainty across international markets.

Yet the headline figure tells only part of the story. The composition of those transactions suggests that Greece is still developing the breadth of buyers normally associated with Europe’s larger investment markets. Private domestic capital and family offices played a particularly prominent role, while traditional institutional investors and Greek listed property companies were more selective about where they deployed money.

The concentration of activity is particularly visible in the largest transaction included in the first-half market figures. National Bank of Greece acquired a portfolio of 100 properties from Prodea Investments for €510.7 million. The transaction had originally been agreed through a preliminary contract in December 2025, with the final transfer scheduled to take place after the relevant conditions were satisfied and no later than May 2026. Cushman & Wakefield Proprius subsequently included the completed transaction in its H1 2026 market assessment.

Its scale matters when interpreting the market. The portfolio was equivalent to around 40% of the €1.27 billion investment total reported for the first six months of the year. Greece therefore demonstrated that it can accommodate very substantial transactions, but the result also illustrates how individual deals can have an unusually large influence on annual or half-year investment figures.

Retail property accounted for more than half of total investment, with approximately €700 million committed to the sector. This apparent dominance needs to be viewed in the context of the Prodea transaction, which contributed heavily to the category. Retail nevertheless continues to attract investors as consumer activity and tourism support demand for well-positioned commercial locations.

Hotels formed the second major destination for capital. Approximately €300 million was invested in hospitality property during the first half of the year. Greece’s tourism industry continues to give hotels an international investment profile that distinguishes the sector from parts of the domestic commercial market, with both Greek and overseas buyers remaining active.

Office transactions amounted to approximately €140 million. The identity of the buyers is particularly significant. Private investors, family offices and businesses purchasing premises for their own occupation were among the main sources of demand. This indicates that office liquidity is being supported by capital whose objectives can differ considerably from those of conventional property funds.

Industrial and logistics property attracted approximately €90 million. Investment volumes remained comparatively modest, but this should not automatically be interpreted as weak demand. The availability of suitable assets continues to influence how much capital can actually enter the Greek market, particularly where investors require modern properties of sufficient size and quality. Limited investment stock remains one of the constraints affecting overall activity.

The increasingly important position of private wealth is one of the more significant changes taking place in Greek property. Family offices and individual investors can move differently from institutional funds. They may accept smaller transactions, consider properties requiring repositioning or take longer-term decisions without having to satisfy the same investment mandates as large international institutions.

That flexibility provides the market with an important source of liquidity. It also means that strong transaction volumes do not necessarily indicate that Greece has already developed a large institutional buyer base comparable with the biggest Western European markets.

Greek property companies remain important, particularly for established income-producing assets, but their purchases now sit alongside capital from wealthy domestic investors, corporate occupiers and strategic buyers. International investors add another layer, although their interest is more visible in selected areas, especially hospitality and retail.

This creates a market with two apparently contradictory characteristics. Greece can attract substantial amounts of capital and execute transactions worth hundreds of millions of euros, yet overall volumes can still be heavily influenced by a small number of deals and buyer groups.

For international investors, that distinction matters. Buying an attractive building is only one part of an investment decision. Funds must also consider how easily they will eventually be able to sell it, how many potential purchasers will exist at the required price level and whether sufficient comparable transactions exist to establish reliable valuations.

A broader buyer base would therefore represent an important next stage in the development of the Greek market. Greater participation by international institutions, domestic property companies, pension and insurance capital, private investors, family offices and corporate buyers would make transaction volumes less dependent on exceptional portfolio sales.

There are already signs of diversification. International capital continues to pursue selected opportunities, domestic private wealth has become increasingly important, and companies buying buildings for their own use provide an additional source of demand. The challenge is turning these different sources of capital into a sufficiently large and consistent pool of buyers across multiple property sectors.

The €1.27 billion invested during the first half of 2026 is consequently an encouraging figure, but perhaps the more important measure of progress will be what happens beneath that number. Greece does not simply need larger transactions to establish itself as a deeper European property investment destination. It needs more buyers capable of completing them.

Source: CIJ.World Research & Analysis Team

Beyond Milan: Italy’s Property Recovery Tests the Strength of Its Regional Cities

Italy’s commercial property market has entered 2026 with international investment firmly returning, but the recovery is exposing a long-standing weakness in the country’s real estate landscape. Capital may be flowing back into Italy, yet the ability to attract large institutional investors remains highly uneven between cities. Investment during the first half of 2026 reached roughly €7.7 billion, putting activity at one of its strongest levels in recent years. Foreign investors have been responsible for a substantial proportion of transactions, confirming that Italy has regained its position on international investment agendas. However, around two-thirds of investment has remained concentrated in Northern Italy, with Milan alone responsible for close to 40% of national volumes.

The figures highlight a central question for the next stage of Italy’s property recovery: can the country develop into a genuinely multi-city investment market, or will international real estate strategies continue to revolve primarily around Milan, supplemented by selected transactions elsewhere? Milan’s advantage extends beyond the amount of capital entering the city. It offers investors depth across offices, residential property, hotels, logistics and regeneration, supported by an established network of developers, lenders, advisers and potential future buyers. This makes both acquiring and eventually selling institutional assets easier to model.

Regional Italy presents a more complicated picture. Investment outside the dominant markets is already substantial, but activity remains fragmented between locations and property sectors. Some cities have developed convincing hotel markets, others benefit from logistics demand or large university populations, while relatively few offer institutional investors opportunities across several asset classes simultaneously. The office sector demonstrates the divide particularly clearly, with Milan and Rome continuing to account for the overwhelming majority of Italian office investment.

This does not necessarily mean that regional cities lack occupier demand. In many cases, the bigger problem is the availability of buildings that meet institutional requirements. Large investors typically require sufficient scale, reliable tenants or operators, modern environmental standards, professional management and a credible prospect of eventually selling the property to another institutional buyer. Without those conditions, even economically successful cities can remain difficult destinations for major international funds.

Logistics is beginning to challenge this geographical concentration. Distribution networks cannot function solely around Milan, while changing supply chains, e-commerce and manufacturing requirements are generating demand across a wider network of locations. Northern logistics corridors remain dominant, but markets further south, including the Bari area, are becoming increasingly relevant as occupiers reconsider national distribution strategies. This could gradually create a larger pipeline of assets suitable for institutional ownership.

Hotels provide an even stronger example of capital moving beyond the country’s largest business centres. Tourism allows investors to underwrite cities using domestic and international visitor demand rather than relying primarily on the strength of the local corporate economy. Florence and Naples therefore have investment characteristics very different from those of regional office markets. Florence already combines international tourism, limited prime supply and strong hospitality demand, while Naples offers potentially greater transformation through tourism growth, regeneration and transport investment.

Student accommodation could become another important driver of geographical diversification. Italy has a significant shortage of professionally operated student housing relative to the size of its university population, and that shortage extends far beyond Milan. Bologna is particularly well positioned because of its large student community, established economy and transport connections. Turin combines major universities with a sizeable metropolitan economy, while Florence attracts substantial domestic and international student demand. Naples and Bari could also attract greater institutional participation as professionally managed accommodation expands.

Regional cities therefore do not necessarily need to recreate Milan’s office market before becoming institutional investment destinations. They could establish their investment credentials through hotels, student housing, rental residential property, logistics or mixed-use regeneration and gradually develop deeper markets around those sectors.

Turin demonstrates how such a transition could develop. Its industrial heritage, universities, infrastructure and large metropolitan population provide several sources of property demand, while the redevelopment of former industrial areas creates opportunities for residential, logistics and mixed-use projects. Bologna offers another model. Its position at the centre of important transport connections, strong university base and established business economy can support logistics, living, hospitality and selected office investment. Its challenge is less about proving underlying demand than generating enough assets of sufficient size for large investors.

Further south, the process remains less developed. Bari could benefit from logistics, university demand, infrastructure investment and its role as an Adriatic commercial gateway. Naples has substantially greater scale and international tourism visibility, together with opportunities created by urban regeneration. Palermo possesses significant tourism and redevelopment potential but remains a more difficult institutional proposition because transaction depth and the supply of large investment-grade assets are more limited.

The distinction is important because institutional capital does not invest in cities simply because their economies are growing. Investors need property that can be valued, financed, operated and eventually sold with reasonable confidence. Liquidity therefore becomes one of the biggest obstacles facing regional markets. A fund buying a major Milan property can reasonably expect several potential institutional purchasers when the asset eventually returns to the market. The buyer pool for an equivalent building in a smaller Italian city may be considerably narrower.

This uncertainty influences pricing from the beginning. Investors may demand higher returns to compensate for the greater difficulty of selling regional assets, potentially creating a gap between owners’ expectations and the prices institutional buyers are willing to pay. Scale presents a related challenge. Global funds deploying hundreds of millions or billions of euros cannot efficiently construct portfolios through numerous small acquisitions. Regional Italy therefore needs larger developments, portfolios and regeneration programmes capable of generating investment opportunities of meaningful size.

Urban regeneration could play an important role in overcoming this limitation. Former industrial sites, railway land and underused urban districts can create combinations of housing, student accommodation, hotels, offices and public infrastructure large enough to attract institutional partners. Successful schemes can also generate the transaction evidence, rental benchmarks and investment track records that make subsequent projects easier for lenders and investors to evaluate.

Greater regional investment would not necessarily mean capital moving uniformly from northern to southern Italy. A more realistic outcome is the development of a network of specialised investment markets. Milan could remain the country’s principal institutional centre while Rome strengthens its position in offices, hotels and living. Bologna could expand around logistics and accommodation, Florence around tourism and living, and Turin around regeneration, industry, logistics and residential property. Naples could develop through hospitality, living and major urban projects, while Bari could gain importance through logistics and university-related investment.

The result would therefore be less a challenge to Milan’s dominance than an expansion of what international investors consider to be investible Italy. The first half of 2026 suggests that this process may already be underway. Capital outside Milan is no longer confined to occasional trophy purchases, but there remains a significant difference between attracting individual transactions and establishing a deep institutional market.

Italy’s next property cycle will consequently be determined by more than the amount of money entering the country. The more significant test will be whether its regional cities can produce enough modern property, transaction volume, development scale and exit liquidity to encourage institutional investors to return repeatedly. If that happens, Italy could gradually evolve from a market dominated by Milan and selected opportunities elsewhere into one where international investors routinely consider several cities when allocating capital.

Source: CIJ.World Research & Analysis Team

 

Austria’s Hotel Deals Are Redrawing the Property Investment Map

Austria’s hotel market is emerging as one of the more active parts of the country’s property investment landscape. Approximately €240 million of hotel transactions were recorded during the first half of 2026, according to Christie & Co., while Colliers estimates that hotels represented around 25% of Austrian commercial property investment during the period. That placed the sector behind retail but ahead of offices and industrial and logistics property, an unusual position at a time when transaction activity across much of the Austrian market remains restrained. The contrast with Vienna’s office market is particularly notable. CBRE recorded approximately €53 million of office transactions in the Austrian capital during the first half of 2026, all completed during the first quarter, with no Vienna office investment transactions recorded during Q2. The hotel and office figures cover different geographic markets and cannot be compared directly, but they nevertheless reveal an important change in where property deals are actually getting completed.

One of the transactions that defined the hotel market during the first half was Deka Immobilien’s acquisition of the former Andaz Vienna Am Belvedere for approximately €92 million. The property was acquired for the WestInvest InterSelect fund and became Hyatt Regency Vienna in April 2026. MHP operates the hotel under a Hyatt franchise arrangement and holds a long-term lease. The deal is important beyond its size because it demonstrates the characteristics that can bring institutional capital into hotel real estate. A major Vienna property, an established international brand, an experienced operator and a long-term contractual structure create an investment proposition that can be assessed alongside more conventional income-producing property.

This does not mean that Austrian hotels as a whole have suddenly become low-risk institutional investments. Hotels remain much more closely connected to the performance of their underlying businesses than most traditional commercial properties. Occupancy, room rates, operating expenses, staffing, management quality and changing visitor demand all influence the income available to support property values. The current investment recovery is therefore highly selective. The strongest hotels can attract institutional buyers, while properties with weaker locations, uncertain operating structures or substantial refurbishment requirements remain much more difficult to finance and trade. Rather than a general hotel boom, Austria is developing a clearer distinction between properties capable of attracting conventional real estate capital and those that remain primarily specialist investments.

Vienna is the most obvious market for this shift. Its hotel sector benefits from a mixture of international leisure tourism, corporate travel, conferences, cultural events and domestic demand. That diversity reduces dependence on a single season or visitor category and can make larger properties more understandable to long-term investors. Scale also matters because institutional property funds generally need transactions large enough to justify the resources required to acquire and manage them. Vienna contains hotels capable of absorbing tens of millions of euros in a single acquisition, giving the city an advantage over smaller Austrian destinations where suitable properties may be scarce.

International brands can strengthen the investment case, although branding alone is not sufficient. The relationship between the property owner and hotel operator is equally important. Hotels can operate under leases, management contracts, franchise agreements or combinations of these structures, and each allocates risk differently between the property owner and operator. In some cases, investors receive relatively predictable rental income. In others, returns are much more directly linked to the hotel’s operating performance. Two hotels of similar size and physical quality can therefore have substantially different investment profiles depending on the financial strength of their operators, the duration of agreements and how operating risks are divided. The Hyatt Regency Vienna transaction demonstrates how these elements can be combined in a structure capable of attracting an institutional property fund, although it does not prove that every large Vienna hotel can achieve the same result.

Outside Vienna, Austria becomes a considerably more diverse hotel investment market. Salzburg combines exceptional international tourism demand with a relatively constrained historic city. Well-located properties can benefit from scarcity, although the smaller market naturally limits the number of large assets available to institutional investors. Innsbruck occupies another position, combining an urban economy with access to Alpine tourism. Its hotels can draw from business visitors, city tourism and mountain-related leisure demand, creating an investment profile different from both Vienna and dedicated resort destinations.

Austria’s Alpine hotel market presents another set of opportunities and risks. Major resorts can attract affluent international visitors and generate strong room revenues, but many properties are more exposed to seasonality and require significant operational expertise. Destination quality becomes almost as important as the building itself. The ability of mountain destinations to generate business throughout the year is becoming increasingly important, with hiking, cycling, wellness and other summer activities capable of broadening the visitor season and reducing dependence on skiing. Over the longer term, investors also need to consider how changing climatic conditions could affect different resorts, particularly where winter tourism remains central to the business model. A large branded Vienna property, a Salzburg city hotel and an Alpine resort may all be classified as hotels, but their income characteristics, buyer pools and risks can be fundamentally different.

Refurbishment requirements further separate the strongest investment opportunities from the rest of the market. Hotels require continuous expenditure to remain competitive. Guest rooms need renovation, public areas require updating, technology evolves and heating, cooling and other building systems eventually need replacement. Improving energy efficiency can add another significant cost. An apparently inexpensive hotel can therefore become a costly investment if substantial renovation is required shortly after acquisition. Conversely, an older property occupying an exceptional location may create an opportunity if the purchase price allows sufficient capital for repositioning.

Existing hotels can sometimes offer an advantage over new development because buyers can examine actual operating performance before committing capital. Historical occupancy, room rates and revenues provide information that does not exist when underwriting a hotel that has yet to be built. Existing properties can still require substantial investment, but the underlying demand is easier to assess. New hotel development carries a different risk because construction costs, financing conditions and future visitor demand must all be estimated several years before opening. That uncertainty can make acquiring and improving existing hotels attractive when development economics remain difficult.

Financing consequently plays a central role in determining which properties can trade. Banks financing hotel acquisitions need confidence not only in the real estate but also in the income generated by the business occupying it. Strong locations, credible operators, sustainable contractual structures and realistic purchase prices can materially strengthen the financing case. Austria’s €240 million of first-half hotel transactions should therefore be interpreted as evidence of liquidity in selected parts of the market rather than proof that financing has become easy across the sector. Investors and lenders remain selective, particularly where significant refurbishment or repositioning is required.

The return of international and institutional capital could nevertheless gradually deepen the market. Global hotel companies increasingly operate properties they do not own, using management and franchise structures that separate the hotel brand from ownership of the real estate. This allows institutional funds and other property investors to own the building while specialist operators manage the hospitality business. That separation can make hotel property easier for conventional real estate investors to understand by providing a clearer distinction between the capital invested in the building and the expertise required to operate it, even though the two remain economically connected.

The first half of 2026 provides evidence that this model can attract meaningful capital in Austria. Hotels represented approximately one quarter of Austrian property investment according to Colliers, compared with around 17% for offices. Individual transactions can significantly influence those percentages in a relatively small market, so the figures should not be interpreted as evidence that hotels have permanently overtaken offices. The more important development is that hotel real estate has become capable of absorbing institutional capital at a time when transaction activity in some traditional property sectors remains weak.

What happens next will determine whether this is a lasting change. Further acquisitions of large Vienna hotels would indicate that institutional demand extends beyond a small number of exceptional properties, while transactions in Salzburg, Innsbruck or major resort destinations would provide evidence that the buyer pool is also broadening geographically. If activity slows after the largest first-half transactions are completed, the institutional hotel market may remain relatively narrow. If transactions continue across different locations and buyer types, hotels could establish a considerably larger role within Austrian property portfolios.

The dividing line will remain asset quality. Investors are unlikely to buy hotels simply because the sector performed strongly during the first half of 2026. Location, operator strength, contractual arrangements, building condition, future expenditure and acquisition price will determine which properties attract capital. Austria’s hotel investment recovery is therefore less about the entire sector becoming institutional and more about a growing group of properties demonstrating that they can meet institutional requirements.

That distinction makes the market particularly interesting while conventional office investment remains subdued. Austria does not need hotels to replace offices as a core property sector for the change to matter. It only needs enough investible hotel assets to provide institutions with a credible alternative when opportunities elsewhere are limited. The first half of 2026 suggests that process is already underway. The next question is whether Austria can produce enough suitable assets to turn several high-profile transactions into a deeper and more permanent institutional hotel investment market.

Source: CIJ.World Research & Analysis Team

Brazil’s Data-Centre Boom Is Creating a New Market for Power-Ready Land

Brazil’s rapid expansion of digital infrastructure is beginning to change the way investors and developers assess land. As artificial intelligence, cloud computing and digital services require increasingly large computing facilities, the decisive factor in choosing a development site is no longer simply location or land cost. Access to sufficient electricity is moving towards the centre of the investment equation.

São Paulo remains the heart of Brazil’s data-centre industry and the largest concentration of capacity in Latin America. Its position reflects the scale of the surrounding economy, extensive telecommunications networks, proximity to corporate customers and an established cluster of operators and technology companies. New facilities continue to be developed across the metropolitan region, including projects capable of supporting the much higher computing densities associated with artificial intelligence.

The scale of the latest developments shows how quickly requirements are changing. Projects planned around Greater São Paulo are increasingly measured in hundreds of megawatts rather than the relatively modest capacities associated with earlier generations of data centres. Ascenty, Ada Infrastructure and Equinix are among the operators expanding in and around the region, while new campuses are incorporating dedicated electrical infrastructure and substantial capacity for future growth.

This expansion is creating a property challenge that conventional industrial development does not face to the same degree. A logistics warehouse can often be developed across a broad range of industrial locations provided there is suitable road access, labour availability and planning permission. A large data centre has a much narrower choice. The site must combine substantial and dependable electricity supply with telecommunications infrastructure, suitable land, security and the ability to obtain the necessary approvals.

Consequently, two parcels of industrial land located relatively close to one another can have very different potential values. A site capable of securing a major electricity connection and accessing multiple fibre routes may have strategic importance to a data-centre developer that bears little relationship to its value for conventional warehousing or manufacturing.

Brazil’s electricity authorities are already having to consider this new source of demand in longer-term network planning. Forecasts indicate that consumption from data centres could increase substantially before the end of the decade. Individual projects can require power on a scale comparable with major industrial operations, meaning that clusters of new facilities can create significant demands on regional transmission and distribution infrastructure.

This changes the development timetable as well. Acquiring land is comparatively straightforward compared with creating additional electricity capacity. New substations, transmission connections and network reinforcements can require long planning and construction periods. Developers able to secure credible access to large quantities of electricity therefore gain an advantage that competitors cannot necessarily reproduce simply by purchasing neighbouring land.

The result could be the emergence of a new hierarchy within Brazil’s industrial property market. At the bottom are sites suitable for conventional commercial development. Above them are locations offering strong telecommunications connections and proximity to established digital clusters. The most strategically valuable sites may increasingly be those where large quantities of electricity can actually be delivered within a commercially viable timeframe.

Brazil has another important advantage in this competition: its electricity system contains a high proportion of renewable generation. For global technology companies seeking to expand computing capacity while managing the environmental impact of their operations, access to renewable electricity can strengthen the country’s appeal compared with markets where additional computing demand remains heavily dependent on fossil-fuel generation.

That advantage does not mean every major project will remain concentrated around São Paulo. In fact, the search for electricity could gradually broaden Brazil’s data-centre geography. Ceará demonstrates what that alternative model could look like. Large digital infrastructure projects around Pecém can combine renewable generation with international telecommunications connectivity and available development land. Fortaleza and Ceará already occupy an important position in international fibre networks because of the subsea cables connecting Brazil with North America, Europe and other markets.

This creates the possibility of two complementary development models. São Paulo can continue serving as Brazil’s principal corporate and cloud-computing centre, supported by its enormous customer base and mature digital ecosystem. Other regions could attract very large computing campuses where access to energy, land and international connectivity outweighs the benefits of being close to the country’s largest commercial centre.

For property investors, this raises a more interesting question than how many data centres Brazil will build. It is whether control over electricity infrastructure will fundamentally change what constitutes valuable development land. Land traditionally derives much of its commercial value from location, permitted use, transport connections and surrounding demand. For digital infrastructure, an additional variable is becoming critical: how many megawatts can realistically be brought to the site, how quickly they can be delivered and how dependable that supply will be.

That could create opportunities well beyond the companies operating the facilities themselves. Landowners, infrastructure investors, developers and energy companies may increasingly compete to identify sites where electricity, fibre and property can be assembled before hyperscale customers enter the development process.

There are also risks. Announced electricity demand does not automatically translate into completed projects, while speculative acquisition of land based on assumed future grid connections could leave investors holding sites that cannot support the anticipated capacity. Water availability, environmental licensing, construction costs and local infrastructure can also affect development feasibility. The growing electricity requirements of data centres may additionally intensify debate about how new generation and network capacity should be allocated between digital infrastructure, industry and other consumers.

For this reason, it would be premature to describe electricity-ready land as a fully established property sector in Brazil. There is not yet enough transparent transactional evidence to demonstrate a consistent national valuation premium for such sites. The direction of the market, however, is becoming clearer. As AI increases the amount of electricity required by computing infrastructure, securing power is moving further towards the beginning of the development process.

Brazil’s next generation of data centres may therefore reshape more than the country’s technology industry. They could change how investors value industrial land itself. In a market where electricity connections can take longer to secure than property, the most important development opportunity may no longer be the largest or best-located parcel of land. It may simply be the site where the power can actually be delivered.

Source: CIJ.World Research & Analysis Team

AI Is Starting to Rebuild Government From the Back Office Out

Artificial intelligence in government is often discussed in terms of surveillance, regulation and national security, but some of the most immediate applications are considerably less dramatic. Across US federal and state government, AI is increasingly being tested against a more familiar problem: ageing technology, administrative backlogs and public employees spending large amounts of time processing documents, reviewing forms and moving information between systems that were never designed to communicate with one another.

At AI4 2026, officials from the US Department of Homeland Security and the states of Utah and Indiana described how AI is beginning to move beyond isolated government experiments and into everyday public administration. Their examples ranged from contract analysis and software development to licensing, Freedom of Information Act requests and interactions between citizens and government agencies. The discussion, moderated by Reuters White House correspondent Jacob Bogage, also revealed a significant shift in how public-sector technology leaders are thinking about artificial intelligence. Rather than viewing AI primarily as a way of reducing government employment, the officials repeatedly described it as a mechanism for removing repetitive administrative work while keeping people responsible for consequential decisions.

That distinction could determine whether AI becomes genuinely useful across government. Public administrations face a combination of pressures that make automation attractive. Many operate legacy technology dating back decades, while the number and complexity of services they provide have expanded. Government employees must comply with extensive privacy, security, procurement and transparency requirements, yet citizens increasingly expect digital services comparable with those available from banks, retailers and technology platforms.

Indiana provides one example of how these pressures are changing technology investment. Rob Falk, chief information officer within the Indiana Secretary of State’s office, described an extensive modernisation programme covering business services, securities regulation, elections and the regulation of motor-vehicle dealers and manufacturers. One of the initial challenges was understanding legacy systems whose original documentation and institutional knowledge had disappeared over time. Rather than manually reconstructing every business rule, Indiana used AI as part of the process of analysing older systems, identifying their logic and helping developers rebuild applications on newer technology.

AI was subsequently introduced elsewhere in the development cycle, including software generation and testing. The state is also incorporating generative AI into public-facing services, including systems intended to guide users through licensing procedures and help review documentation. Behind those interfaces, AI can perform some of the preliminary administrative work previously handled manually. Falk said the changes have reduced workload in some back-office processes by approximately 60–70%. That figure represents Indiana’s reported experience with particular implementations rather than an independently established productivity benchmark, but it illustrates the scale of efficiency that government technology leaders believe may be available.

The more important point is what happens to the time that is released. Indiana’s strategy is not based on automatically reducing headcount as administrative work disappears. Instead, employees can spend more time dealing directly with complicated cases and citizens who need assistance. That could represent one of AI’s more important effects on public administration. Government digitisation has historically attempted to move people away from human interaction by placing services online. AI potentially creates the opposite possibility: automating enough repetitive administrative work that government employees have more time for situations where human interaction is actually valuable.

The US Department of Homeland Security faces the same challenge on a much larger scale. Roman Jankowski, DHS Chief Privacy Officer and Chief Freedom of Information Act Officer, described administrative processes in which information moves between systems that were never designed to work together. Freedom of Information Act processing is a particularly demanding example. DHS handles an exceptionally large volume of requests, including cases involving immigration records and interactions with federal agencies. Some requests require individuals to provide identifying information that must then be processed through separate systems before relevant records can be located.

Historically, parts of this process involved physical documents and repeated scanning. Even after information began arriving electronically, administrative procedures could still require employees to transfer it manually between systems. AI and automation provide an opportunity to remove some of these intermediate steps and accelerate the processing of requests. The objective is not to allow an algorithm to decide independently what sensitive government information should be released. Decisions involving privacy, national security, law-enforcement information and legally protected data remain subject to human review and statutory requirements. Instead, AI can reduce the mechanical work surrounding those decisions.

This division between processing and responsibility appeared repeatedly throughout the panel. AI can retrieve information, compare documents, identify discrepancies and recommend actions. Humans remain accountable for consequential decisions. Utah is pursuing a similar approach through its Division of Technology Services. The state has established a broader AI programme alongside an Office of Artificial Intelligence Policy and has adopted an explicitly people-centred strategy in which technology is intended to strengthen human capability rather than automatically replace workers.

One of Utah’s most interesting examples involves government contracts. State agencies process large numbers of agreements containing clauses that must comply with legislation, administrative rules and internal policies. Reviewing those documents manually can require significant amounts of specialist time. Officials initially experimented with a general-purpose AI assistant but found that it could not reliably handle the complexity of the task. The problem was not simply understanding the contract. The system needed to compare different sections against numerous statutes, policies and administrative requirements.

Utah subsequently developed a more specialised architecture involving several AI agents, each responsible for analysing different elements of a contract. According to Christian Napier, Director of AI at Utah’s Division of Technology Services, the resulting system can perform its analysis in around ten minutes for some documents and has reduced the time required from contract analysts by approximately 75%. Again, the percentage is a result reported by the state team rather than an independent assessment. Nevertheless, the example demonstrates an important lesson for organisations adopting AI: a general chatbot and a purpose-built AI workflow are not the same thing.

Early disappointment with artificial intelligence may sometimes reflect the way the technology has been deployed rather than a fundamental limitation of AI. Asking a general-purpose assistant to perform a highly specialised regulatory task without the necessary architecture, data and controls can produce unreliable results. Breaking the problem into defined components and designing the system around the actual workflow can generate very different outcomes.

This is likely to become increasingly important as governments move from experimentation towards production. The first phase of generative AI encouraged employees to use broad conversational tools for many different purposes. The next phase is likely to involve narrower systems designed around particular administrative functions.

Government technology departments are simultaneously reconsidering what they should build themselves and what they should purchase from technology companies. None of the officials argued that governments should develop their own frontier AI models. The enormous investment already being made by private technology companies makes that economically difficult to justify for most public authorities. Instead, governments can use commercially available cloud infrastructure and models while concentrating their internal resources on the business processes unique to government. That means understanding regulations, workflows, citizen requirements and the restrictions governing public data, then building applications around those requirements.

The result is likely to be a hybrid public-sector technology market. Large cloud and AI companies provide computing infrastructure and foundational technology, specialist vendors provide particular applications, systems integrators help connect them, and government technology teams develop or customise the workflows that are specific to their agencies.

For technology suppliers, this changes the nature of the public-sector opportunity. Government buyers on the panel showed little interest in generic claims that AI could solve any problem. They wanted suppliers that understood specific administrative challenges, could demonstrate functioning products and had a credible route through government security, procurement and implementation requirements.

Speed is becoming another consideration. Traditional public-sector technology programmes can take several years to procure and deploy. AI development cycles are considerably shorter, creating tension between rapidly changing technology and government processes designed around stability and long planning horizons. Indiana’s technology leadership described working around much shorter implementation periods, attempting to deliver projects within months rather than allowing modernisation programmes to extend indefinitely. That approach will not be appropriate for every government system, particularly those involving critical infrastructure or national security, but it demonstrates how expectations are changing.

Internal capacity remains a constraint. Utah, for example, has hundreds of software engineers distributed across state government but only a small central AI engineering team. That requires central specialists to work with individual agencies, transfer knowledge and help existing development teams adopt the technology. AI itself may make that decentralisation easier. Business users increasingly have tools that allow them to prototype interfaces, describe workflows and participate more directly in application design. Work that previously passed sequentially from a department to an IT team can increasingly be developed collaboratively.

This creates opportunities but also governance challenges. Government employees deal with some of the most sensitive information held by any organisation, including financial records, immigration information, law-enforcement material and personally identifiable data. AI systems cannot simply be connected across every database because doing so would undermine legal restrictions governing why information was collected and how it may be used.

Utah’s approach to conversational AI illustrates the issue. The state has developed a common architecture that agencies can use while keeping personal information within the systems responsible for it. Information can be accessed for an authorised interaction without creating a new central repository containing everything known about an individual. This principle becomes increasingly important as AI makes combining information technically easier. A system may be capable of connecting records from multiple agencies and producing a comprehensive picture of an individual, but technical capability does not automatically create legal authority to do so.

Public-sector AI therefore faces a constraint that many commercial deployments encounter to a lesser degree: information must remain connected to the purpose for which government was authorised to collect and use it. DHS faces the same issue at federal level. Privacy decisions can involve determining whether information may legally be shared between agencies or released publicly. Those decisions can depend on legislation, the circumstances of an individual case and potential consequences for national security, operational security or personal privacy.

AI may help organise the material required to make those decisions, but the officials argued that human responsibility cannot disappear. Jankowski described cases where lawyers review the circumstances and provide legal analysis before a final decision is made about whether information can be shared.

The distinction suggests that the familiar concept of keeping a person involved in an automated process may itself evolve. Rather than humans merely checking AI output at the final stage, public officials remain responsible for defining the boundaries within which automated systems operate. That is particularly relevant where AI systems make recommendations concerning licences, regulatory approvals or other decisions affecting individuals and businesses. Automation can identify whether documentation appears complete or whether an application meets defined conditions, but government remains accountable for the final outcome.

Privacy is only one of the risks. Cybersecurity is becoming equally important as malicious actors gain access to more capable AI tools. Utah’s technology leadership identified the need to strengthen thousands of existing applications against AI-assisted attacks as one of its most pressing concerns. DHS faces an additional problem through the transparency obligations of government itself. Information released individually through legitimate public-record requests can sometimes be combined to reveal patterns or operational details that were not obvious from any single document. AI could make that type of analysis substantially faster.

Government agencies will therefore find themselves using AI both to improve transparency and to defend systems against increasingly sophisticated attempts to exploit information. The economics of AI will also matter. Public-sector organisations operate under taxpayer scrutiny and cannot assume that every task should be sent to the most powerful and expensive model available. Utah’s strategy includes matching the technology to the complexity of the task, using smaller models where appropriate rather than automatically relying on frontier systems.

That principle could become increasingly relevant across both government and business. A narrowly defined administrative process may require classification or extraction rather than sophisticated reasoning. Using a smaller specialised model can reduce computing and operating costs while potentially producing more predictable results.

The panel also highlighted a structural feature of government that makes AI adoption particularly interesting. Utah officials said the state’s executive branch employs roughly the same number of people today as it did decades ago while serving a much larger population and providing substantially more services. Regardless of the exact historical comparison, the underlying challenge is familiar across public administrations: service demand can grow considerably faster than government staffing.

AI provides one potential way to increase administrative capacity without expanding employment at the same rate. That does not necessarily mean reducing the workforce. It can mean allowing the same number of employees to process more transactions while directing their attention towards cases that require judgement, communication and expertise.

The implications extend beyond government budgets. Public-sector productivity affects businesses directly. Licensing delays can postpone openings and investment. Slow regulatory reviews can hold up projects. Inefficient company-registration systems increase administrative costs. Delays in accessing government information create uncertainty for individuals and businesses. Better public-sector technology therefore functions partly as economic infrastructure. A government capable of processing routine administrative activity more quickly can reduce friction across the private economy.

This is where the concept of AI for the public good becomes commercially significant. The economic value of artificial intelligence will not come only from companies becoming more productive. It may also come from governments becoming easier to interact with.

The biggest obstacle may ultimately be institutional rather than technological. AI models and development tools are changing on cycles measured in months, while government procurement, regulation and technology governance have traditionally evolved much more slowly. Public authorities must therefore find ways to move faster without abandoning the privacy, security and accountability requirements that distinguish government from ordinary commercial technology deployment.

That balance will define the next stage of public-sector AI. Moving too slowly risks leaving employees trapped in inefficient systems while citizens receive services that increasingly fall behind private-sector expectations. Moving too quickly could introduce security vulnerabilities, privacy violations or automated decisions that governments cannot adequately explain.

The examples from Utah, Indiana and DHS suggest a more pragmatic route. Start with repetitive administrative work, build specialised systems around clearly defined processes, maintain human responsibility for consequential decisions and measure whether the technology genuinely reduces cost or processing time.

If that model succeeds, some of the most consequential applications of artificial intelligence may prove surprisingly ordinary. They may not involve autonomous governments or algorithms making public policy. They may involve contracts being reviewed faster, licences being processed more efficiently, information requests taking less time and public employees spending fewer hours moving data between ageing computer systems.

For citizens and businesses interacting with government, those seemingly mundane improvements could ultimately be among AI’s most tangible benefits.

Source: CIJ.World Research & Analysis Team

French Retail Is Entering an Era Where Location Alone Is No Longer Enough

France’s retail property market is becoming increasingly difficult to describe through a single set of investment figures. Capital has returned to the sector, but buyers are concentrating on properties where customer demand, tenant appeal and the long-term usefulness of the underlying site can be demonstrated. Elsewhere, lower valuations are exposing assets whose difficulties may require far more than a change of ownership to resolve. Approximately €1.8 billion was invested in French retail property during the first half of 2026, broadly in line with the corresponding period a year earlier. Yet the apparent stability of the market conceals considerable concentration. A handful of major transactions generated more than half of total first-half volume, demonstrating that investors are prepared to acquire retail property but remain highly selective about where they commit capital.

This selectivity is creating a widening gap between exceptional high-street properties, successful retail parks, dominant shopping centres and weaker secondary assets. The investment question is consequently changing. Finding a property whose valuation has fallen is relatively easy. Determining whether that discount represents an opportunity is much harder. Paris provides the clearest evidence that investors have not abandoned physical retail. Large transactions involving properties on the Champs-Élysées contributed substantially to investment activity during the first half of the year. Assets on globally recognised shopping streets retain characteristics that are extremely difficult to reproduce elsewhere: international visibility, tourism, scarcity and access to retailers seeking flagship locations.

That does not make prime high-street property immune to changes in consumer behaviour. Retailers still have to justify expensive stores and landlords remain exposed to changing brand strategies. But the strongest streets offer something that secondary locations frequently cannot: a reason for major occupiers to maintain a physical presence even as online sales continue to expand.

Retail parks are benefiting from a different set of advantages. France has more than 8 million square metres of retail-park space across hundreds of locations, and the format continues to attract both occupiers and investors. Development patterns during 2026 reinforce this position. The majority of French retail space completed during the first half of the year was located in retail parks rather than traditional enclosed shopping centres. Investment transactions involving the format also contributed meaningfully to first-half activity.

Retail parks often provide relatively straightforward access, parking, large units and occupancy costs that can suit retailers focused on convenience and value. Their tenant mixes can extend beyond conventional shops to supermarkets, restaurants, fitness, leisure and services. Vacancy statistics provide another indication of the divergence. Market research published during 2026 showed average vacancy across French retail parks considerably below that recorded across shopping centres. The comparison needs to be treated carefully because individual properties vary enormously, but it helps explain why investors increasingly evaluate retail according to format and asset quality rather than treating the sector as a single market.

The position of shopping centres is considerably more complicated. Successful regional centres with large catchments, strong transport connections and substantial visitor numbers can remain highly defensible assets. Where customers have access to shopping, restaurants, entertainment and services within a single destination, physical retail can continue to provide an experience that online commerce cannot fully replace. The greater challenge lies with secondary centres that have lost part of their original purpose.

Many were designed when consumers had fewer shopping alternatives and when conventional fashion and merchandise stores generated reliable footfall. Today, those centres compete simultaneously with online retail, retail parks, stronger destination centres and changing consumer spending patterns. A centre suffering from vacancy can respond by changing its tenant mix. Restaurants, fitness, healthcare, entertainment and other services can generate visits that are not directly dependent on conventional shopping. In the right location, this can restore relevance.

But not every struggling property can be repaired through leasing strategy. A centre may have too much space for its catchment, an inefficient configuration, weak transport connections or insufficient surrounding purchasing power. It may require substantial expenditure while offering limited potential for higher rents. In those circumstances, the decline in investment value can reflect a problem with the underlying real estate rather than temporary investor caution.

This is where French retail is beginning to present two fundamentally different types of discounted opportunity. The first is a property that has been repriced but remains commercially relevant. Higher financing costs, weaker investment sentiment or temporary vacancy may have reduced its value, while the underlying customer base and occupier demand remain intact. Purchasing such an asset at a lower basis can potentially create an attractive investment opportunity. The second is a property where the traditional retail model itself is becoming increasingly difficult to sustain.

The distinction matters because a higher investment yield does not necessarily compensate for structural weakness. A centre acquired inexpensively can still destroy value if tenants continue leaving, income falls and increasing amounts of capital are required to maintain the property. For these assets, investors increasingly need to look beyond the existing retail income and consider the underlying site.

Large retail properties can occupy substantial areas of developed land with established road connections, utilities and planning histories. Some also contain extensive surface parking. Where the surrounding location is strong, these characteristics can potentially create opportunities to reorganise or intensify the property. The future use does not necessarily have to remain entirely retail. Depending on local demand and planning, parts of a site might eventually accommodate housing, healthcare, leisure, hospitality, workplaces or other commercial activities. Retail could remain an important component while occupying a smaller proportion of a broader mixed-use destination.

This is an opportunity rather than an established nationwide conversion trend. Redeveloping existing retail property can be complicated, expensive and slow. Existing tenants may have contractual rights that restrict construction, while planning changes can take years to secure. The physical structure of a shopping centre can also limit what is realistically possible. An asset that appears to occupy valuable land may prove difficult to divide or redevelop without extensive demolition. Infrastructure may require replacement and new uses can create additional requirements for transport, schools, public space or other facilities.

For investors, the acquisition price therefore needs to reflect not only today’s income but the cost and time required to create tomorrow’s property. France’s evolving approach to land consumption adds another dimension. Planning and environmental policies increasingly encourage more efficient use of already developed sites rather than continual expansion onto previously undeveloped land. The practical impact varies considerably between locations and individual projects, but existing commercial sites could become increasingly important where additional development is possible.

This could favour retail properties whose buildings are ageing but whose land remains strategically useful. A poorly performing shopping centre in a strong metropolitan location may therefore have a completely different investment outlook from an equally weak centre in a declining catchment. Both may show similar vacancy and yields, but only one may possess realistic redevelopment potential. That distinction is likely to become increasingly important as investors search for value.

Consumer conditions provide another reason for caution. French retail spending remained relatively subdued during the first half of 2026, while online commerce continued to expand. Physical retail nevertheless continued to attract customers, demonstrating that the issue is not simply whether people still visit shops. The more important question is which places they choose to visit.

Properties offering convenience, experience, strong brands or useful services have a clearer reason to remain part of consumers’ routines. Locations without those advantages face greater pressure to reinvent themselves. This makes tenant mix increasingly important to property value. A supermarket can generate regular visits. Restaurants can extend trading hours. Fitness and healthcare can bring customers to a property repeatedly throughout the week. Leisure can turn a shopping trip into a longer visit, while discount and value retailers can attract consumers even during periods of weaker household confidence.

The strongest retail properties can therefore become broader commercial destinations rather than collections of conventional shops. This evolution also changes the role of asset management. During an era of strong retail expansion, landlords could often rely on market growth and rising rents to support values. In today’s more selective environment, performance increasingly depends on active decisions about tenants, capital expenditure, redevelopment and the long-term function of the property.

The difference between a successful repositioning and an unsuccessful attempt can be enormous. An investor considering a discounted French retail asset consequently needs to determine whether the weakness is temporary or permanent, whether vacancy can realistically be reduced, whether the catchment supports the amount of retail space already present, how much capital is required to modernise the property and whether alternative uses can be introduced if conventional retail demand continues to weaken. The time required to achieve that transformation is equally important because financing costs, operating expenses and vacancies continue while redevelopment is being pursued.

The answers will increasingly determine which assets recover and which continue losing relevance. Prime high streets will remain a separate market driven partly by scarcity and international demand. Successful retail parks appear well positioned where they combine convenience, affordable occupancy and strong catchments. Dominant shopping centres can continue attracting consumers when they provide sufficient reasons to visit. The greatest uncertainty surrounds the middle and lower parts of the market.

Some secondary properties may become attractive as valuations fall because their problems are capable of being fixed. Others may eventually be worth more as redevelopment sites than as conventional shopping destinations. The French retail investment market is therefore moving beyond a simple argument about whether physical retail is recovering.

Approximately €1.8 billion of transactions during the first half of 2026 demonstrates that capital is willing to own retail. What investors are increasingly unwilling to do is assume that every retail property deserves to survive in its existing form. The next opportunity may be an undervalued shopping centre, an underdeveloped retail park or an ageing commercial site capable of supporting a completely different mix of uses.

But falling prices alone will not identify the winners. In the next phase of the French retail market, the most important skill may be recognising the difference between a property that has become cheap and one that has become irrelevant.

Source: CIJ.World UK Research & Analysis Team

front page info
LATEST NEWS